-
Entity
-
Individual
-
Location
-
C/O Intercept Pharmaceuticals, Inc., 18 Desbrosses Street, New York, New York
-
Summary
-
The estimated net worth of Barbara Gayle Duncan is at least $964 K dollars as of June 21, 2024. Barbara Gayle Duncan is the Director of HALOZYME THERAPEUTICS, INC. and owns shares of HALOZYME THERAPEUTICS, INC. (HALO) stock worth about $728 K. Barbara Gayle Duncan is the Director of Atea Pharmaceuticals, Inc. and owns shares of Atea Pharmaceuticals, Inc. (AVIR) stock worth about $236 K.